128 related articles for article (PubMed ID: 30506645)
1. Comparison of five different scoring methods in the evaluation of inflammatory infiltration (tumor-infiltrating lymphocytes) in superficial spreading and nodular melanoma.
Němejcová K; Tichá I; Bártů M; Kodet O; Důra M; Jakša R; Michálková R; Dundr P
Pigment Cell Melanoma Res; 2019 May; 32(3):412-423. PubMed ID: 30506645
[TBL] [Abstract][Full Text] [Related]
2. Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas.
Lin RL; Wang TJ; Joyce CJ; Mihm MC; Murphy GF; Lian CG; Lin JY
Melanoma Res; 2016 Oct; 26(5):524-7. PubMed ID: 26974966
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.
Fortes C; Mastroeni S; Mannooranparampil TJ; Passarelli F; Zappalà A; Annessi G; Marino C; Caggiati A; Russo N; Michelozzi P
Melanoma Res; 2015 Aug; 25(4):306-11. PubMed ID: 25933208
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex.
Sinnamon AJ; Sharon CE; Song Y; Neuwirth MG; Elder DE; Xu X; Chu EY; Ming ME; Fraker DL; Gimotty PA; Karakousis GC
J Am Acad Dermatol; 2018 Aug; 79(2):245-251. PubMed ID: 29518458
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
Clemente CG; Mihm MC; Bufalino R; Zurrida S; Collini P; Cascinelli N
Cancer; 1996 Apr; 77(7):1303-10. PubMed ID: 8608507
[TBL] [Abstract][Full Text] [Related]
7. A Novel Numerical Scoring System for Melanoma Tumor-infiltrating Lymphocytes Has Better Prognostic Value Than Standard Scoring.
Saldanha G; Flatman K; Teo KW; Bamford M
Am J Surg Pathol; 2017 Jul; 41(7):906-914. PubMed ID: 28368925
[TBL] [Abstract][Full Text] [Related]
8. Tumor Infiltrating Lymphocytes (TILs) May be Only an Independent Predictor of Nodal Involvement but not for Recurrence and Survival in Cutaneous Melanoma Patients.
Tas F; Erturk K
Cancer Invest; 2017 Sep; 35(8):501-505. PubMed ID: 28799813
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes.
Grotz TE; Vaince F; Hieken TJ
Melanoma Res; 2013 Apr; 23(2):132-7. PubMed ID: 23344159
[TBL] [Abstract][Full Text] [Related]
10. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
11. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
Hendry S; Salgado R; Gevaert T; Russell PA; John T; Thapa B; Christie M; van de Vijver K; Estrada MV; Gonzalez-Ericsson PI; Sanders M; Solomon B; Solinas C; Van den Eynden GGGM; Allory Y; Preusser M; Hainfellner J; Pruneri G; Vingiani A; Demaria S; Symmans F; Nuciforo P; Comerma L; Thompson EA; Lakhani S; Kim SR; Schnitt S; Colpaert C; Sotiriou C; Scherer SJ; Ignatiadis M; Badve S; Pierce RH; Viale G; Sirtaine N; Penault-Llorca F; Sugie T; Fineberg S; Paik S; Srinivasan A; Richardson A; Wang Y; Chmielik E; Brock J; Johnson DB; Balko J; Wienert S; Bossuyt V; Michiels S; Ternes N; Burchardi N; Luen SJ; Savas P; Klauschen F; Watson PH; Nelson BH; Criscitiello C; O'Toole S; Larsimont D; de Wind R; Curigliano G; André F; Lacroix-Triki M; van de Vijver M; Rojo F; Floris G; Bedri S; Sparano J; Rimm D; Nielsen T; Kos Z; Hewitt S; Singh B; Farshid G; Loibl S; Allison KH; Tung N; Adams S; Willard-Gallo K; Horlings HM; Gandhi L; Moreira A; Hirsch F; Dieci MV; Urbanowicz M; Brcic I; Korski K; Gaire F; Koeppen H; Lo A; Giltnane J; Rebelatto MC; Steele KE; Zha J; Emancipator K; Juco JW; Denkert C; Reis-Filho J; Loi S; Fox SB
Adv Anat Pathol; 2017 Nov; 24(6):311-335. PubMed ID: 28777143
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma.
Tas F; Erturk K
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2721-2729. PubMed ID: 33611652
[TBL] [Abstract][Full Text] [Related]
13. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis.
Schatton T; Scolyer RA; Thompson JF; Mihm MC
Methods Mol Biol; 2014; 1102():287-324. PubMed ID: 24258985
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Ren M; Dai B; Kong YY; Lv JJ; Cai X
Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
[TBL] [Abstract][Full Text] [Related]
16. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
van Houdt IS; Sluijter BJ; Moesbergen LM; Vos WM; de Gruijl TD; Molenkamp BG; van den Eertwegh AJ; Hooijberg E; van Leeuwen PA; Meijer CJ; Oudejans JJ
Int J Cancer; 2008 Aug; 123(3):609-15. PubMed ID: 18498132
[TBL] [Abstract][Full Text] [Related]
17. Presence of histological regression as a prognostic factor in cutaneous melanoma patients.
Tas F; Erturk K
Melanoma Res; 2016 Oct; 26(5):492-6. PubMed ID: 27380112
[TBL] [Abstract][Full Text] [Related]
18. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
19. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
